Loading organizations...
Otter Capital is a private equity firm that strategically invests equity in established businesses. The firm focuses on identifying companies that demonstrate robust growth prospects, significant market presence, and a clear path to sustained profitability. Its investment approach prioritizes fundamental value and operational excellence, engaging with companies that present compelling long-term potential.
The firm was founded in 2001 by John Pasquesi, who established Otter Capital to pursue diverse private equity investment opportunities. Pasquesi brought extensive prior experience in financial management and investment strategy to the firm, leveraging his background to build a distinctive investment philosophy centered on thorough analysis and patient capital deployment.
Otter Capital partners with the management teams of its portfolio companies, providing capital and strategic guidance to foster long-term value creation. The firm aims to support these businesses in achieving their full potential, driving sustainable growth and generating superior returns for its investors through disciplined investment and active partnership, envisioning enduring success for its portfolio.
Otter Capital has 6 tracked investments across 4 companies. The latest tracked deal is $15.0M Other Equity in BioConsortia in April 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 1, 2024 | BioConsortia | $15.0M Other Equity | Otter Capital | — |
| Dec 20, 2023 | NewLeaf Symbiotics | $45.0M Series D | Peter Odemark | Leaps BY Bayer, S2G Ventures |
| Jan 17, 2022 | Botanical Solutions | $6.1M Series A | Otter Capital | — |
| Mar 29, 2018 | BioConsortia | $10.0M Series D | Otter Capital | Khosla Ventures |
| Nov 7, 2016 | BioConsortia | $12.0M Debt / Other Equity | Robert Hisaoka, Khosla Ventures, Otter Capital | KEN Wegner, Square 1 Bank |
| Aug 27, 2014 | Green & Grow | $6.0M Series B | Otter Capital | — |